Targeting Functional Biomarkers in Schizophrenia with Neuroimaging.
Targeting Functional Biomarkers in Schizophrenia with Neuroimaging.
复制标题
DOI：
10.2174/1381612822666160127113912
复制
发表时间：
2016
影响因子：
3.1
通讯作者：
Tregellas JR
中科院分区：
文献类型：
--
作者：
Wylie KP;Smucny J;Legget KT;Tregellas JR
精神疾病如精神分裂症的许多最令人衰弱的症状仍然没有得到很好的治疗。因此，迫切需要开发新的治疗方法。不幸的是，随着研究性化合物进入临床试验，与其高失败率相关的成本导致制药公司缩小规模或取消开发这些药物所需的研究计划。增加研究性化合物成功概率的一种方法是结合识别生物靶点的替代方法，以便更有效地筛选新药。一个很有前途的方法来实现这一目标的精神药物是使用功能性磁共振成像（fMRI）。功能磁共振成像研究神经回路，揭示了产生幻觉等症状的生物学。一旦确定，相关的神经回路可以有针对性的药物干预和功能磁共振成像测量这些药物的反应。这篇综述介绍了早期使用的功能磁共振成像在这种情况下，并讨论了α 7烟碱受体激动剂3-（2，4-二甲氧基苯亚甲基）anabaseine（DMXB-A），作为一个例子的潜在价值的功能磁共振成像精神药物的开发。
Many of the most debilitating symptoms for psychiatric disorders such as schizophrenia remain poorly treated. As such, the development of novel treatments is urgently needed. Unfortunately, the costs associated with high failure rates for investigational compounds as they enter clinical trials has led to pharmaceutical companies downsizing or eliminating research programs needed to develop these drugs. One way of increasing the probability of success for investigational compounds is to incorporate alternative methods of identifying biological targets in order to more effectively screen new drugs. A promising method of accomplishing this goal for psychiatric drugs is to use functional magnetic resonance imaging (fMRI). fMRI investigates neural circuits, shedding light on the biology that generates symptoms such as hallucinations. Once identified, relevant neural circuits can be targeted with pharmacologic interventions and the response to these drugs measured with fMRI. This review describes the early use of fMRI in this context, and discusses the alpha7 nicotinic receptor agonist 3-(2,4-dimethoxybenzylidene) anabaseine (DMXB-A), as an example of the potential value of fMRI for psychiatric drug development.